The latest update is out from Bausch Health Companies ( (TSE:BHC) ).
Bausch Health has filed a supplement to its proxy statement in response to Carl Icahn and affiliates’ cash-settled equity swaps covering 90 million of its common shares, giving Icahn an economic interest in 34% of the company. The company has also adopted a shareholder rights plan to prevent any entity from acquiring 20% or more of its shares without complying with exemptions, aiming to protect against creeping take-over bids and ensure value-enhancing alternatives for all shareholders.
Spark’s Take on TSE:BHC Stock
According to Spark, TipRanks’ AI Analyst, TSE:BHC is a Neutral.
Bausch Health Companies’ stock score reflects strong revenue growth and cash flow generation but is weighed down by high leverage and persistent net losses. Technical indicators show bearish momentum, while valuation remains unattractive due to negative earnings. Positive earnings call and corporate events provide some optimism, yet financial stability concerns persist.
To see Spark’s full report on TSE:BHC stock, click here.
More about Bausch Health Companies
Bausch Health Companies Inc. is a global, diversified pharmaceutical company focused on delivering better healthcare outcomes. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health through its controlling interest in Bausch + Lomb Corporation.
YTD Price Performance: -40.55%
Average Trading Volume: 2,583,334
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.74B
See more insights into BHC stock on TipRanks’ Stock Analysis page.